SG11201809064QA - Chimeric neurotoxins - Google Patents
Chimeric neurotoxinsInfo
- Publication number
- SG11201809064QA SG11201809064QA SG11201809064QA SG11201809064QA SG11201809064QA SG 11201809064Q A SG11201809064Q A SG 11201809064QA SG 11201809064Q A SG11201809064Q A SG 11201809064QA SG 11201809064Q A SG11201809064Q A SG 11201809064QA SG 11201809064Q A SG11201809064Q A SG 11201809064QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- english
- unless
- indicated
- Prior art date
Links
- 239000002581 neurotoxin Substances 0.000 title abstract 3
- 231100000618 neurotoxin Toxicity 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000008520 organization Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 0 1111111111111111111111111111111111111111111111111111111111111111111111111 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/191315 Al 09 November 2017 (09.11.2017) WIP0 I PCT (51) International Patent Classification: A61K 38/00 (2006.01) C07K 14/33 (2006.01) (21) International Application Number: PCT/EP2017/060821 (22) International Filing Date: 05 May 2017 (05.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1607901.4 05 May 2016 (05.05.2016) GB (71) Applicant: IPSEN BIOPHARM LIMITED [GB/GB]; Unit 9 Ash Road - Wrexham Industrial Estate, Wrexham LL13 9UF (GB). (72) Inventor: LIU, Sai Man; 11 Haynes Road, Oxford OX3 OSE (GB). (74) Agent: GROT, Emmanuelle; IPSEN PHARMA, 65 quai Georges Gorse, 92100 Boulogne Billancourt (FR). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (81) =_ = — = Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (84) = = = = _ _ = = = = = Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) — — 1-1 in Il M Il 0\ Il IN 1-1 (54) Title: CHIMERIC NEUROTOXINS 0 ei (57) : The present invention relates to chimeric neurotoxins with enhanced properties and their use in therapy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1607901.4A GB201607901D0 (en) | 2016-05-05 | 2016-05-05 | Chimeric neurotoxins |
PCT/EP2017/060821 WO2017191315A1 (en) | 2016-05-05 | 2017-05-05 | Chimeric neurotoxins |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809064QA true SG11201809064QA (en) | 2018-11-29 |
Family
ID=56297235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809064QA SG11201809064QA (en) | 2016-05-05 | 2017-05-05 | Chimeric neurotoxins |
Country Status (23)
Country | Link |
---|---|
US (2) | US11434265B2 (en) |
EP (2) | EP3452071B1 (en) |
JP (3) | JP7421862B2 (en) |
KR (2) | KR102643970B1 (en) |
CN (2) | CN116333158A (en) |
AR (1) | AR108689A1 (en) |
AU (2) | AU2017260389B2 (en) |
BR (1) | BR112018072587A2 (en) |
CA (1) | CA3020640A1 (en) |
DK (1) | DK3452071T3 (en) |
EA (1) | EA201892386A1 (en) |
ES (1) | ES2866899T3 (en) |
GB (1) | GB201607901D0 (en) |
HU (1) | HUE054856T2 (en) |
IL (1) | IL262575B (en) |
MX (1) | MX2018013141A (en) |
PL (1) | PL3452071T3 (en) |
PT (1) | PT3452071T (en) |
SA (1) | SA518400335B1 (en) |
SG (1) | SG11201809064QA (en) |
TW (2) | TWI751157B (en) |
UA (1) | UA126563C2 (en) |
WO (1) | WO2017191315A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2847241T3 (en) | 2012-05-30 | 2021-08-02 | Harvard College | Genetically modified botulinum neurotoxin |
BR112015003591B1 (en) | 2012-11-21 | 2022-02-01 | Ipsen Bioinnovation Limited | USES OF LYS-C AND METHODS FOR MANUFACTURING A PROTEOLYTICLY PROCESSED POLYPEPTIDE |
HUE057258T2 (en) * | 2015-03-26 | 2022-05-28 | Harvard College | Engineered botulinum neurotoxin |
GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
SG10201912099TA (en) * | 2016-06-08 | 2020-02-27 | Childrens Medical Center | Engineered botulinum neurotoxins |
WO2018039506A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
TWI810228B (en) * | 2017-12-20 | 2023-08-01 | 英商艾普森生物製藥有限公司 | Treatment of autonomic disorders |
SE542539C2 (en) * | 2018-02-26 | 2020-06-02 | Toxotech Ab | Chimeric botulinum neurotoxin heavy chain binding domain |
EP3775046A1 (en) * | 2018-04-06 | 2021-02-17 | Dupont Polymers, Inc. | Additive manufacturing compositions |
US20220016221A1 (en) | 2018-12-05 | 2022-01-20 | Ipsen Biopharm Limited | Treatment of symptoms of traumatic brain injury |
EP3753568A1 (en) | 2019-06-21 | 2020-12-23 | Fastox Pharma SA | Composition modulating botulinum neurotoxin effect |
GB201914034D0 (en) * | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
GB202001353D0 (en) | 2020-01-31 | 2020-03-18 | Ipsen Biopharm Ltd | Treatment of skin conditions |
GB202003813D0 (en) | 2020-03-16 | 2020-04-29 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
AU2021238924A1 (en) | 2020-03-16 | 2022-08-25 | Ipsen Biopharm Limited | Modified botulinum neurotoxin for treating limb spasticity |
GB202011055D0 (en) | 2020-07-17 | 2020-09-02 | Ipsen Bioinnovation Ltd | Treatment of post-operative pain |
GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
GB202104294D0 (en) * | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
KR20230163470A (en) | 2021-03-30 | 2023-11-30 | 입센 바이오팜 리미티드 | Treatment of pain & inflammatory disorders |
CN117396217A (en) | 2021-03-30 | 2024-01-12 | 益普生生物制药有限公司 | Catalytically inactive clostridial neurotoxins for use in the treatment of pain and inflammatory diseases |
WO2023041934A1 (en) | 2021-09-16 | 2023-03-23 | Ipsen Biopharm Limited | Modified bont/a for use in the treatment of cervical dystonia |
CA3228712A1 (en) | 2021-09-23 | 2023-03-30 | Nicolae GRIGORE | Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject |
GB202113602D0 (en) | 2021-09-23 | 2021-11-10 | Ipsen Biopharm Ltd | Treatment of a disorder affecting an eyelid muscle of a subject |
WO2023089343A1 (en) | 2021-11-22 | 2023-05-25 | Ipsen Biopharm Limited | Treatment of pain |
GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
GB202206361D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of a facial dystonia |
GB202206362D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
GB202206348D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
GB202206353D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1099445A3 (en) | 1993-06-10 | 2001-09-05 | Allergan, Inc. | Treatment of neuromuscular disorders and conditions with different botulinum serotype |
US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US20040126396A1 (en) | 1993-12-28 | 2004-07-01 | Allergan, Inc. | Botulinum toxin treatment for strabismus |
US5670484A (en) | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
US5714469A (en) | 1994-09-01 | 1998-02-03 | Smithkline Beecham Corporation | Method of treating sepsis |
US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
US6545126B1 (en) * | 1999-03-18 | 2003-04-08 | Wisconsin Alumni Research Foundation | Chimeric toxins |
US6767544B2 (en) | 2002-04-01 | 2004-07-27 | Allergan, Inc. | Methods for treating cardiovascular diseases with botulinum toxin |
US6358917B1 (en) | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
US6265379B1 (en) | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
US6261572B1 (en) | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
US6337075B1 (en) | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
US6143306A (en) | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
US6524580B1 (en) | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US6299893B1 (en) | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
US6565870B1 (en) | 2000-04-28 | 2003-05-20 | Allergan, Inc. | Methods for treating bone tumors |
US6306403B1 (en) | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
US6903187B1 (en) | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
US6827931B1 (en) | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
US6623742B2 (en) | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
US7255866B2 (en) | 2001-09-17 | 2007-08-14 | Allergan, Inc. | Botulinum toxin therapy for fibromyalgia |
US6921538B2 (en) | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
AU2003287155A1 (en) | 2002-10-15 | 2004-05-04 | Allergan, Inc. | Botulinum toxin dental therapies and procedures |
US7238357B2 (en) | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
US6838434B2 (en) | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
US7220422B2 (en) | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
US20040253274A1 (en) | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
DE102004043009A1 (en) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transport protein for introducing chemical compounds into nerve cells |
US7465457B2 (en) * | 2005-04-14 | 2008-12-16 | Wisconsin Alumni Research Foundation | Method for preparing botulinum neurotoxin type A light chain |
DE102005019302A1 (en) * | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier for targeting nerve cells |
RU2524429C2 (en) * | 2008-08-29 | 2014-07-27 | Мерц Фарма Гмбх Унд Ко. Кгаа | Clostridial neurotoxins with modified persistence |
GB0903006D0 (en) * | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
JP5764550B2 (en) | 2009-04-14 | 2015-08-19 | エムシーダブリユー リサーチ フオンデーシヨン インコーポレーテツド | Genetically engineered botulinum neurotoxin |
DK2571509T3 (en) * | 2010-05-20 | 2016-10-24 | Allergan Inc | degradable clostridiumtoksiner |
US8853360B2 (en) | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
GB201108108D0 (en) * | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
EP2798077A2 (en) * | 2011-12-31 | 2014-11-05 | Allergan, Inc. | Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A |
ES2847241T3 (en) * | 2012-05-30 | 2021-08-02 | Harvard College | Genetically modified botulinum neurotoxin |
BR112015003591B1 (en) * | 2012-11-21 | 2022-02-01 | Ipsen Bioinnovation Limited | USES OF LYS-C AND METHODS FOR MANUFACTURING A PROTEOLYTICLY PROCESSED POLYPEPTIDE |
GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
US9216210B2 (en) * | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
US10647750B2 (en) * | 2015-01-09 | 2020-05-12 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
HUE057258T2 (en) * | 2015-03-26 | 2022-05-28 | Harvard College | Engineered botulinum neurotoxin |
KR20180070563A (en) * | 2015-08-27 | 2018-06-26 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Compositions and methods for treating pain |
GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
SG10201912099TA (en) * | 2016-06-08 | 2020-02-27 | Childrens Medical Center | Engineered botulinum neurotoxins |
MX2019000151A (en) * | 2016-07-08 | 2019-08-29 | Childrens Medical Center | A novel botulinum neurotoxin and its derivatives. |
WO2018039506A1 (en) * | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
WO2018172264A1 (en) * | 2017-03-24 | 2018-09-27 | Merz Pharma Gmbh & Co. Kgaa | Improved use of botulinum neurotoxin in the treatment of sialorrhea |
US10329543B2 (en) * | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
WO2019152380A1 (en) * | 2018-01-30 | 2019-08-08 | Children's Medical Center Corporation | Production of botulinum neurotoxins using bacillus systems |
SG11202009895TA (en) * | 2018-04-27 | 2020-11-27 | Krystal Biotech Inc | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications |
-
2016
- 2016-05-05 GB GBGB1607901.4A patent/GB201607901D0/en not_active Ceased
-
2017
- 2017-05-05 JP JP2018558218A patent/JP7421862B2/en active Active
- 2017-05-05 PT PT177243359T patent/PT3452071T/en unknown
- 2017-05-05 AU AU2017260389A patent/AU2017260389B2/en active Active
- 2017-05-05 US US16/094,254 patent/US11434265B2/en active Active
- 2017-05-05 TW TW106114984A patent/TWI751157B/en active
- 2017-05-05 EP EP17724335.9A patent/EP3452071B1/en active Active
- 2017-05-05 BR BR112018072587-0A patent/BR112018072587A2/en unknown
- 2017-05-05 UA UAA201812004A patent/UA126563C2/en unknown
- 2017-05-05 EA EA201892386A patent/EA201892386A1/en unknown
- 2017-05-05 SG SG11201809064QA patent/SG11201809064QA/en unknown
- 2017-05-05 KR KR1020187034781A patent/KR102643970B1/en active IP Right Grant
- 2017-05-05 TW TW111106023A patent/TWI832162B/en active
- 2017-05-05 KR KR1020247007005A patent/KR20240033165A/en active Application Filing
- 2017-05-05 PL PL17724335T patent/PL3452071T3/en unknown
- 2017-05-05 ES ES17724335T patent/ES2866899T3/en active Active
- 2017-05-05 CN CN202210871196.6A patent/CN116333158A/en active Pending
- 2017-05-05 HU HUE17724335A patent/HUE054856T2/en unknown
- 2017-05-05 EP EP21161122.3A patent/EP3889168A1/en active Pending
- 2017-05-05 CA CA3020640A patent/CA3020640A1/en active Pending
- 2017-05-05 AR ARP170101177A patent/AR108689A1/en unknown
- 2017-05-05 MX MX2018013141A patent/MX2018013141A/en unknown
- 2017-05-05 CN CN201780026413.9A patent/CN109069576B/en active Active
- 2017-05-05 DK DK17724335.9T patent/DK3452071T3/en active
- 2017-05-05 WO PCT/EP2017/060821 patent/WO2017191315A1/en active Application Filing
-
2018
- 2018-10-24 IL IL262575A patent/IL262575B/en unknown
- 2018-10-29 SA SA518400335A patent/SA518400335B1/en unknown
-
2021
- 2021-11-11 AU AU2021266312A patent/AU2021266312B2/en active Active
-
2022
- 2022-04-27 JP JP2022073033A patent/JP2022105100A/en active Pending
- 2022-07-12 US US17/811,958 patent/US20230025090A1/en active Pending
-
2023
- 2023-10-18 JP JP2023179513A patent/JP2024010008A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809064QA (en) | Chimeric neurotoxins | |
SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
SG11201804934PA (en) | Novel Compounds | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201901528RA (en) | Proteolytically cleavable chimeric polypeptides and methods of use thereof | |
SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201909303TA (en) | Point of delivery cold slurry generation | |
SG11201808306PA (en) | Treatment of cancer with tg02 | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
SG11201901251SA (en) | Aminopyrimidines as alk inhibitors | |
SG11201908275XA (en) | Peptides and methods for the treatment of diabetes | |
SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same |